Anti-Human CD11a (Efalizumab) - Fc Muted

Quality Tested by Leinco FC The suggested concentration for Efalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Next Day 2-8°C

CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.

FA
B
CyTOF®
ELISA
IHC

Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroinflammation, Neuroscience

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Efalizumab. Clone hu1124 recognizes human CD11a. This product is for research use only.

AB_2894025

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

CD11a is expressed on all leukocytes.

Human CD11a

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.